aphl survey hiv diagnostic testing utilization barbara g. werner, phd ma state laboratory institute...
TRANSCRIPT
![Page 1: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/1.jpg)
APHL SurveyHIV Diagnostic Testing Utilization
Barbara G. Werner, PhD
MA State Laboratory Institute
February 28, 2005
![Page 2: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/2.jpg)
Information about Current Testing Status to Address New Challenges
• New EIA screening tests
• Expanded use of rapid tests
• Additional uses of nucleic acid amplification tests (NAAT)
• Confirmatory testing in different settings– The old 9 letter word “algorithm”
![Page 3: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/3.jpg)
Survey Format and Launch
• Electronic Survey on APHL LabNet
• Content and design input from APHL/CDC HIV Steering Committee
• Timeframe: July/August 2004
• Sent to 56 Jurisdictions– PH labs in all states, DC and 5 territories– Limitation: Local/county PH labs not included
![Page 4: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/4.jpg)
Survey Respondents
• 49 Responses; overall 88%– 48 States, one territory
• 7 No response
![Page 5: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/5.jpg)
Questions about HIV Testing
• EIA and Confirmatory Testing
• Use of NAAT
• Acute infection testing
• Incidence surveillance testing
• Rapid HIV Testing
• CLIA Limited Public Health Use Exception
![Page 6: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/6.jpg)
HIV Screening Tests Utilized (%)*
bioMerieux Vironostika HIV-1 63bioMerieux Viron HIV-1 PLUS O 0Bio-Rad Gen Sys HIV-1 rLAV 20Bio-Rad HIV 1/2 Synthetic Peptide 10 Bio-Rad HIV-1/HIV-2 PLUS O 10Abbott HIVAB HIV-1/2 20Genetic Systems HIV-2 EIA 18bioMerieux Oral Viron HIV-1 61
*Percent of responding labs reporting use within past year
![Page 7: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/7.jpg)
EIAs Used for 1o Screening of Sera
• bioMerieux Vironostika HIV-1 30 labs*• Bio-Rad Gen. Sys. rLAV 8• Abbott HIV-1/2 7**• Bio-Rad HIV1/HIV2 Plus O 4
* 2 labs used in tandem --with Genetic Systems rLAV or Bio-Rad HIV-1/2 Synthetic Peptide** Used as backup in one other state
Genetic Systems HIV-2 EIA 9 labsNot necessarily for initial screen
![Page 8: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/8.jpg)
Changes in Use of Screening Tests
• 11 indicated that they plan to change to another EIA within next year
• Decisions pending validation
![Page 9: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/9.jpg)
Confirmatory Tests Used by Labsfor Serum/Plasma
• 34 Bio-Rad Gen Sys HIV-1 Western blot
• 11 Calypte Camb Biotech HIV–1 WB
• 7 Fluorgnost HIV-1 IFA– 4 in conjunction with Western blot for serum
• Only three states planned to switch confirmatory test within year
![Page 10: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/10.jpg)
Testing Oral Fluid Specimens
• 30 labs used Oral Vironostika HIV-1
• 28 labs used Orasure HIV-1 WB assay
![Page 11: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/11.jpg)
Nucleic Acid Amplification Testing
• 25 labs reported capability
• 14 labs currently performing NAAT– 11 for patient monitoring– 3 for acute infection screening
• 2 additional states indicated interest in initiating NAAT for acute infection screening within the next year
![Page 12: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/12.jpg)
Seroincidence Testing
• At time of survey, 10 states performed incidence testing, as part of CDC or local surveillance efforts
• Note: IND for incidence testing using Vironostika EIA to be terminated by CDC
![Page 13: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/13.jpg)
Involvement with HIV Rapid Testing
• Approximately one-half reported delivering at least one training course (CDC or own) and 2 additional labs had developed course but had not implemented
• With limited follow-up, some labs were involved with confirmatory testing, some with QA responsibilities
![Page 14: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/14.jpg)
CLIA Limited PH Use Exception
• Six states reported use of the Exception, allowing multiple labs to operate under a single CLIA certificate
• 4 of 6 permit CBOs, etc. to use for HIV rapid testing– On follow up, all 4 provide confirmatory
testing and oversight
![Page 15: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/15.jpg)
Conclusions and Challenges • Communication issues
– Knowledge of changing assays, incidence testing, etc
• Confirmation of new tests with Group O antigens, as well as HIV-2, is an issue as is limited choice for confirmatory tests
• Integration of rapid tests– Confirmatory testing– Educational assistance for QA
• Likelihood of new or different algorithms in different settings
![Page 16: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/16.jpg)
Efforts to Improve Communication
• APHL/CDC HIV Steering Committee• APHL Updates for Members
– Electronic and print, including Survey Report for HIV Testing Utilization
• APHL ID Committee– Interim Position Statement on Rapid Tests
• Presentations/Roundtables– APHL/ASTHO Annual Meetings– HIV Diagnostics Conference– HIV Prevention Conference
![Page 17: APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005](https://reader036.vdocument.in/reader036/viewer/2022082709/56649da75503460f94a93016/html5/thumbnails/17.jpg)
Acknowledgments
• Anthony Tran, APHL Staff
• APHL/CDC HIV Steering Committee
• APHL Members